With the increasing promise of long-term survival with immune checkpoint blockade (ICB)
therapies, particularly for patients with advanced melanoma, clinicians and investigators are …

Responsiveness to immune checkpoint blockade (ICB) therapy in cancer is currently
predicted by disparate individual measures–with varying degrees of accuracy–including …

Over the past decade, the advent of molecular techniques and deeper understanding of the
tumor microenvironment (TME) have enabled the development of a multitude of …

Abstract PD‐1/PD‐L1 (programmed cell death‐1 and programmed death‐ligand 1)
inhibitors utilization in neoadjuvant therapy has been assessed in tumors. This study …

Soft tissue sarcomas (STSs) are rare mesenchymal tumors. With more than 80 histological
subtypes of STSs, data regarding novel biomarkers of strong prognostic and therapeutic …

The origins of cancer vaccines date back to the 1800s. Since then, there have been
significant efforts to generate vaccines against solid and hematologic malignancies using a …

Background Neoadjuvant immunotherapy has preliminarily been effective in multiple
resectable cancers. However, its safety is still largely unknown. Methods A systematic …

O melanoma cutâneo é o tumor cutâneo com maior taxa de mortalidade. De facto, o
diagnóstico de doença localmente avançada está associado a pior prognóstico, com …

Increasing evidence has showed the immune response is an important indicator for
predicting therapeutic e cacy, and the prognosis value of the in ltration degree of immune …